Seite auswählen

The U.S. pharmaceutical company Bristol-Myers Squibb (BMS) has experienced a slump in sales due to the amortisation of billions of dollars, seeing them slip into the red. The bottom line is that the Group recorded a loss of $711 million, contrasting to last year’s profit of $969 million.

And in terms of revenue, that also went downhill: after $5.35 billion in the prior year, BMS sales of $3.73 billion in the third quarter of 2012 are 30 percent less.


[ilink url=““] Link zur Quelle (BMS)[/ilink]